Evidence map›Paper›PMID 24987096›Full record

ArticlemBio2014

IQGAP1 is important for activation of caspase-1 in macrophages and is targeted by Yersinia pestis type III effector YopM.

Lawton K Chung, Naomi H Philip, Valentina A Schmidt, Antonius Koller, Till Strowig, Richard A Flavell, Igor E Brodsky, James B Bliska

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. The pyrin inflammasome in host-microbe interactions.Current opinion in microbiology · 2020
    Review
  11. A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  12. Review
  13. Article
  14. Chromosomally-EncodedFrontiers in cellular and infection microbiology · 2019
    Article
  15. The Pyrin Inflammasome in Health and Disease.Frontiers in immunology · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lawton K ChungDepartment of Molecular Genetics and Microbiology and Center for Infectious Diseases, Stony Brook University, Stony Brook, New York, USA.
Naomi H PhilipDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;
Valentina A SchmidtDepartment of Medicine, School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Antonius KollerProteomics Center, School of Medicine, Stony Brook University, Stony Brook, New York, USA;
Till StrowigDepartment of Immunobiology and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.
Richard A FlavellDepartment of Immunobiology and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.
Igor E BrodskyDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;
James B BliskaDepartment of Molecular Genetics and Microbiology and Center for Infectious Diseases, Stony Brook University, Stony Brook, New York, USA james.bliska@stonybrook.edu.
Stony Brook University · USUniversity of Pennsylvania · USHoward Hughes Medical Institute · USYale University · US

Funding

Viral Pathogenesis and TherapeuticsU54AI057158 · NIAID · WADSWORTH CENTER · PI LEVY, DAVID E · 2003 to 2014
$100.8M
Regulation of host innate and adaptive immunity by bacterial type III effectorsR01AI099222 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI BLISKA, JAMES B · 2012 to 2025
$5.9M
MOLECULAR AND CELL BIOLOGY OF INFECTIOUS DISEASEST32AI007539 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI KONOPKA, JAMES B · 1998 to 2023
$3.6M
Modulation of Inflammasome Activation by YersiniaR01AI103062 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRODSKY, IGOR E · 2013 to 2016
$1.7M
Acquisition of a Thermo Scientific Orbitrap XL Hybrid FT Mass SpectrometerS10RR025072 · NCRR · STATE UNIVERSITY NEW YORK STONY BROOK · PI IDEN, CHARLES R · 2008 to 2008
$851k
Role of Caspase-8 in Yersinia virulence and host defenseR21AI109267 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRODSKY, IGOR E · 2014 to 2015
$440k
Howard Hughes Medical InstituteNCRR NIH HHS S10 RR025072NCRR NIH HHS S10RR025072NIAID NIH HHS R01 AI099222NIAID NIH HHS R01AI099222NIAID NIH HHS R01 AI103062NIAID NIH HHS R01AI103062NIAID NIH HHS R21 AI109267NIAID NIH HHS R21AI109267NIAID NIH HHS T32 AI007539NIAID NIH HHS U54 AI057158NIAID NIH HHS U54AI057158
6 · The paper itself

Abstract

YopM is a leucine-rich repeat (LRR)-containing effector in several Yersinia species, including Yersinia pestis and Y. pseudotuberculosis. Different Yersinia strains encode distinct YopM isoforms with variable numbers of LRRs but conserved C-terminal tails. A 15-LRR isoform in Y. pseudotuberculosis YPIII was recently shown to bind and inhibit caspase-1 via a YLTD motif in LRR 10, and attenuation of YopM(-) YPIII was reversed in mice lacking caspase-1, indicating that caspase-1 inhibition is a major virulence function of YopM(YPIII). To determine if other YopM proteins inhibit caspase-1, we utilized Y. pseudotuberculosis strains natively expressing a 21-LRR isoform lacking the YLTD motif (YopM(32777)) or ectopically expressing a Y. pestis 15-LRR version with a functional (YopM(KIM)) or inactivated (YopM(KIM) D271A) YLTD motif. Results of mouse and macrophage infections with these strains showed that YopM(32777), YopM(KIM), and YopM(KIM) D271A inhibit caspase-1 activation, indicating that the YLTD motif is dispensable for this activity. Analysis of YopM(KIM) deletion variants revealed that LRRs 6 to 15 and the C-terminal tail are required to inhibit caspase-1 activation. YopM(32777), YopM(KIM), and YopM(KIM) deletion variants were purified, and binding partners in macrophage lysates were identified. Caspase-1 bound to YopM(KIM) but not YopM(32777). Additionally, YopM(KIM) bound IQGAP1 and the use of Iqgap1(-/-) macrophages revealed that this scaffolding protein is important for caspase-1 activation upon infection with YopM(-) Y. pseudotuberculosis. Thus, while multiple YopM isoforms inhibit caspase-1 activation, their variable LRR domains bind different host proteins to perform this function and the LRRs of YopM(KIM) target IQGAP1, a novel regulator of caspase-1, in macrophages. Importance: Activation of caspase-1, mediated by macromolecular complexes termed inflammasomes, is important for innate immune defense against pathogens. Pathogens can, in turn, subvert caspase-1-dependent responses through the action of effector proteins. For example, the Yersinia effector YopM inhibits caspase-1 activation by arresting inflammasome formation. This caspase-1 inhibitory activity has been studied in a specific YopM isoform, and in this case, the protein was shown to act as a pseudosubstrate to bind and inhibit caspase-1. Different Yersinia strains encode distinct YopM isoforms, many of which lack the pseudosubstrate motif. We studied additional isoforms and found that these YopM proteins inhibit caspase-1 activation independently of a pseudosubstrate motif. We also identified IQGAP1 as a novel binding partner of the Yersinia pestis YopM(KIM) isoform and demonstrated that IQGAP1 is important for caspase-1 activation in macrophages infected with Yersinia. Thus, this study reveals new insights into inflammasome regulation during Yersinia infection.

Indexed as

AnimalsBacterial ProteinsCaspase 1Cells, CulturedFemaleMacrophagesMiceMice, KnockoutYersinia pestisBacterial ProteinsCaspase 1

Identifiers

PMID24987096
PMCPMC4161239
OpenAlexW2148581259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.